deficiencies – Pharma GMP

Top OSD GMP Deficiencies Identified in FDA and EU Inspections

digi — Wed, 26 Nov 2025 04:18:04 +0000

Top OSD GMP Deficiencies Identified in FDA and EU Inspections Comprehensive Step-by-Step Guide: GMP Checklist for Oral Solid Dosage Manufacturing Deficiencies Manufacturing oral solid dosage (OSD) forms under current Good Manufacturing Practices (cGMP) demands a rigorous and systematic approach to compliance. Even with well-established pharmaceutical quality systems, regulatory inspections by authorities such as the U.S....

Common Sampling Plan Deficiencies Noted by FDA Inspectors

digi — Wed, 26 Nov 2025 02:57:04 +0000

Common Sampling Plan Deficiencies Noted by FDA Inspectors Addressing Common Deficiencies in In Process Sampling Plans for Tablets In the pharmaceutical industry, ensuring the quality and compliance of tablet manufacturing depends heavily on robust in process sampling plans. Regulatory authorities such as the FDA consistently identify issues related to sampling during inspections, which can lead...

Inspection Cases: Cross Contamination Deficiencies and Lessons Learned

digi — Wed, 26 Nov 2025 01:18:04 +0000

Inspection Cases: Cross Contamination Deficiencies and Lessons Learned Inspection Cases: Cross Contamination Deficiencies and Lessons Learned Cross contamination prevention in manufacturing is a fundamental pillar of pharmaceutical Good Manufacturing Practice (GMP). Strict control of cross contamination is essential to assure patient safety, product quality, and regulatory compliance in the pharmaceutical industry. Despite comprehensive regulations and...

Inspection Findings on Weak Change Control and Unauthorised Modifications

digi — Tue, 25 Nov 2025 20:03:04 +0000

Inspection Findings on Weak Change Control and Unauthorised Modifications Addressing Weak Change Control and Unauthorised Modifications: A Step-by-Step GMP Tutorial In the pharmaceutical industry, robust change control systems are essential to maintaining product quality, patient safety, and regulatory compliance. However, regulatory inspections frequently uncover deficiencies such as unauthorized changes, poor impact assessment, and missing records,...

Inspection Findings on Weak Training and Competency Programs

digi — Tue, 25 Nov 2025 19:42:04 +0000

Inspection Findings on Weak Training and Competency Programs Step-by-Step Guide to Addressing Training and Competency Inspection Findings in Pharmaceutical GMP Training and competency are foundational elements of a compliant pharmaceutical manufacturing environment. Regulatory agencies such as the FDA, EMA, MHRA, PIC/S, and WHO routinely identify deficiencies related to training programs during GMP inspections. These training...

Inspection Findings on Poor Documentation Practices in Pharma Sites

digi — Tue, 25 Nov 2025 18:57:04 +0000

Inspection Findings on Poor Documentation Practices in Pharma Sites Inspection Findings on Poor Documentation Practices in Pharmaceutical Manufacturing Sites Accurate and reliable documentation is the cornerstone of compliance in pharmaceutical manufacturing. Regulatory authorities such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global agencies consistently emphasize the criticality...

Inspection Findings on Weak Deviation and CAPA Management in Manufacturing

digi — Tue, 25 Nov 2025 17:48:04 +0000

Inspection Findings on Weak Deviation and CAPA Management in Manufacturing Effective Management of Manufacturing Deviations and CAPA: Addressing Weaknesses Identified in Inspections Manufacturing deviations and CAPA management remain critical focal points during regulatory inspections conducted by FDA, EMA, MHRA, and other global authorities. Repeated inspection findings highlight systemic weaknesses such as weak CAPA, repeat deviations,...

Inspection Findings on Inadequate Visual Inspection Programs

digi — Tue, 25 Nov 2025 17:09:04 +0000

Inspection Findings on Inadequate Visual Inspection Programs Comprehensive Step-by-Step Guide to Visual Inspection of Injectables GMP Requirements Visual inspection of parenteral products is a critical control point in pharmaceutical manufacturing to ensure product quality and patient safety. Manufacturers must comply with strict visual inspection of injectables GMP requirements to detect defects such as particulates, container...

Common BMR Deficiencies Found in FDA and EU GMP Inspections

digi — Tue, 25 Nov 2025 14:51:04 +0000

Common BMR Deficiencies Found in FDA and EU GMP Inspections Step-by-Step Guide to Identifying and Addressing Common BMR Deficiencies in GMP Batch Manufacturing Records (BMRs) are the cornerstone of pharmaceutical manufacturing quality systems. They ensure complete traceability, facilitate compliance with regulatory standards, and support product quality and patient safety. However, observations and deficiencies associated with...

Inspection Findings on Weak CAPA and Deviation Handling in QC Labs

digi — Tue, 25 Nov 2025 14:42:04 +0000

Inspection Findings on Weak CAPA and Deviation Handling in QC Labs Step-by-Step Tutorial Guide on Managing QC Laboratory Deviations and CAPA Effective management of qc laboratory deviations and capa is a critical component of pharmaceutical Good Manufacturing Practice (GMP) compliance. Inspection authorities including the FDA, EMA, MHRA, and PIC/S routinely identify deficiencies in the handling...